You're contacting media contact of this press release

Title: OceansBio Ltd Announces Its Entry Into Device Similar - Starting a New Era in Implantable Electroceuticals

New York, NY, United States, 26th Aug 2025 - OceansBio Ltd., a leading innovator in biomedical technology, today announced its entry into the emerging era of “Device Similar” for implantable electroceuticals. With a focus on neurological disorders such as Parkinson’s disease, epilepsy, depression, and chronic pain, OceansBio is positioning itself at the forefront of this transformative shift in medical device innovation.OceansBio Ltd.’s Vision for Device SimilarsBuilding on the established concept of biosimilars in the pharmaceutical industry, Device Similars are designed to replicate the function, quality, and safety of original implantable devices once patents expire, at a fraction of the cost. OceansBio Ltd. is developing advanced solutions to ensure greater accessibility for patients requiring neurostimulation therapies.“Just as biosimilars revolutionized the accessibility of biologic treatments, Device Similars hold the potential to make life-changing electroceutical therapies more affordable worldwide,” said Hyunung Lee, spokesperson for OceansBio Ltd.Understanding Device SimilarsWhile biosimilars reproduce complex biological medicines, Device Similars must duplicate sophisticated electronic medical devices with precision. This includes electronics, mechanics, embedded software, and biocompatibility, all subject to rigorous safety and quality standards for long-term use in the human body.Unlike biosimilars, regulatory approval pathways for Device Similars can leverage mechanisms such as the FDA’s 510(k) clearance, provided substantial equivalence to an existing approved device is demonstrated.Opportunities and ChallengesThe introduction of Device Similars represents a significant opportunity to expand access to vital neurological treatments by lowering costs. Howe...

This press release is issued by King Newswire